Organogenesis Inc. Announces Acquisition of Dermagraft® from Shire Organogenesis Inc. announced that it has purchased the Dermagraft® assets (human fibroblast-derived dermal substitute) from Shire plc. Dermagraft is approved for the treatment of nonhealing diabetic foot ulcers in the U.S. and Canada. [Organogenesis Inc.] Press Release Moderna Launches Onkaido Therapeutics to Focus on the Development of mRNA Therapeuticsâ„¢ in Oncology with $20 Million Capital Commitment Moderna Therapeutics announced the creation of Onkaido Therapeutics, a new venture focused exclusively on developing mRNA-based oncology treatments. Onkaido Therapeutics will launch with $20 million in committed capital from Moderna. [Moderna Therapeutics] Press Release Alnylam Acquires Investigational RNAi Therapeutic Assets from Merck Alnylam Pharmaceuticals, Inc. announced the acquisition of Merck’s wholly owned subsidiary Sirna Therapeutics, Inc., comprising intellectual property and RNAi assets including pre-clinical therapeutic candidates, chemistry, siRNA-conjugate and other delivery technologies. [Alnylam Pharmaceuticals, Inc.] Press Release Spark Therapeutics Achieves Recruitment Goal in Phase III Gene Therapy Clinical Study for Inherited Blindness Spark Therapeutics has reached its patient recruitment goal for its most advanced clinical program, a Phase III study for inherited retinal dystrophies caused by mutations in the RPE65 gene. [Spark Therapeutics] Press Release Merck Initiates Rolling Submission of U.S. Biologics License Application for MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma Merck said it has started a rolling submission to the U.S. Food and Drug Administration of a Biologics License Application for MK-3475, the company’s investigational anti-PD-1 immunotherapy, for patients with advanced melanoma who have been previously treated with ipilimumab. [Merck] Press Release BioLineRx Announces Regulatory Submission for Novel Stem Cell Mobilization Treatment BioLineRx announced that it has filed the necessary regulatory submissions to commence a Phase I trial for BL-8040, a novel treatment for the mobilization of stem cells from the bone marrow to the peripheral blood circulation. [BioLineRx] Press Release Pluristem Receives Key Placental Cell Therapy Patent in Australia Pluristem Therapeutics, Inc. announced it has been granted a new patent in Australia. Patent #2008300185, titled “Methods for Cell Expansion and Uses of Cells and Conditioned Media Produced thereby for Therapy,” covers the use of adherent placental cells for the treatment of ischemia, which is a restriction of blood supply to tissues, and for treatments of conditions requiring connective tissue repair or regeneration. [Pluristem Therapeutics, Inc.] Press Release Cytonet Submits European Approval Application for Liver Cell Therapy to Treat Urea Cycle Disorders in Children Cytonet announced that the European Medicines Agency has validated its Marketing Authorization Application seeking approval of its liver cell therapy for the treatment of Urea Cycle Disorders in children. [The Cytonet Group] Press Release |